Industry: Life Sciences
Life sciences fundraising advisory
Biotech, pharma and medtech investors fund milestones, not science alone. We turn your data into the deck, model and target list that specialist funds expect.
- Investor lists and funding data for drugs, devices and tools
- Decks and models built around trial milestones
- Waveup prepares investor materials for life sciences companies: $3B+ raised for 600+ startups since 2014
In short
What is life sciences fundraising advisory?
Life sciences fundraising advisory is help raising money for a biotech, pharma, medtech or research-tools company. The advisor builds what investors will test: the deck, the financial model, the valuation and the investor list. Venture investors put $30.5B into biopharma startups in 2025. They pay for milestones, so your case must show what each round proves.
- Who it's for
- Biotech, pharma, medtech and research-tools companies, pre-seed to Series D+
- What we build
- Investor deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 5 November 2026. Sources are under each section.
Is life sciences funding coming back in 2026?
Yes, for companies with data or a clear path to it. Venture money and IPOs are rising again, but investors back fewer, larger rounds.
The opportunity
Big drugmakers must replace medicines that lose patent protection. Many of the replacements come from younger companies.
- Patent expiries open a growth gap that deals must fill
- AI is changing how new drug candidates are found
- Medtech buyers keep acquiring device makers
The problem
Investors now back fewer companies with bigger cheques. In 2026, Series B and later rounds took about 72% of biopharma venture money.
Market size
How big is the life sciences market, and what is driving it?
Start with medicines. IQVIA expects global spending on them to pass $2.6 trillion by 2030. Four forces shape where investors put their money:
- Patent expiries: EY projects a $370B growth gap by 2032 as blockbusters lose exclusivity
- Dealmaking: life sciences M&A reached $240B in 2025, by EY's count
- AI: EY counts a 256% rise in the potential value of deals for AI platforms
- Rare diseases: half of the FDA's new drugs in 2025 were for rare diseases
Venture capital
How much life sciences venture capital is there in 2026?
Biopharma venture funding grew two years running, to $30.5B in 2025. J.P. Morgan expects about $33B in 2026 if the current pace holds.
biopharma venture rounds in 2025, down from 829 in 2021
biopharma rounds of $100M or more in 2026, to 30 September
raised by seed and Series A biopharma companies in 2026, across 170 rounds
Who invests in life sciences startups?
Specialist biotech VCs, multi-stage funds, medtech investors, lenders and EU grants. Seven examples follow; our list of life sciences venture capital firms has more.
Investor database
Biotech investors in our database
The funds with the most biotech investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by biotech investments
Investments by industry
- Healthtech & Wellness47%
- Biotech26%
- Pharma20%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Chicago, United States
- Invests in
- USA
502 investments in total, 23 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness41%
- Biotech36%
- Pharma18%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Boston, United States
- Invests in
- USA
141 investments in total, 22 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness38%
- Biotech33%
- Pharma17%
- Rounds
- SeedSeries ASeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- San Francisco, United States
- Invests in
- USA
196 investments in total, 20 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness44%
- Biotech27%
- Pharma15%
- Rounds
- Series ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- Boston, United States
439 investments in total, 18 tagged Biotech.Open the full fund profile
Investments by industry
- Healthtech & Wellness46%
- Biotech25%
- Pharma16%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- United States
- Invests in
- Israel, Europe, USA +1
231 investments in total, 17 tagged Biotech.Open the full fund profile
From our investor database.
Why do life sciences startups struggle to raise?
Our Fundraising 2025 study asked 56 VCs why they pass. Burn and missed milestones were among the top reasons. In life sciences, both weigh more, because revenue comes late.
Most drugs fail in trials
Most drugs that enter human trials never reach patients. In BIO's 2011–2020 data, only 7.9% of Phase I drugs won approval.
What investors ask
- Which result does this round buy, and what is the company worth after it?
What your deck shows
- One milestone the money reaches, with a date
- Cash runway past that readout
Fewer first cheques
Investors want data before they lead a first round. First-time biopharma financings fell to $1.7B in Q3 2026, the lowest since Q3 2025.
What investors ask
- Why fund you now, before the data, rather than after it?
What your deck shows
- What each step removes from the risk
- Who could lead your next round, and why
Competition from China
Big drugmakers now license many drugs first developed in China. In 2026, those made up 51% of their licensing deals with large upfront payments.
What investors ask
- Why license your asset if a cheaper one exists elsewhere?
What your deck shows
- What sets your molecule apart: mechanism, data, patents
- A development plan that is fast and lean
Big deal values, little cash upfront
Licensing deals announce big totals, but most of the money depends on milestones. Upfront cash was just 6% of announced biopharma licensing value in 2026.
What investors ask
- What would a partner really pay, and when?
What your deck shows
- Comparable deals by upfront cash, not headline value
- A partnering plan tied to your data readouts
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
The science in plain words, built around your next milestone.
Trial costs, runway and milestone timing in one model.
A range from comparable deals and risk-adjusted cash flows.
Specialist VCs, crossover funds and pharma investors for your stage.
IP, trial data and regulatory files, indexed for diligence.
For a sale, or a pharma buyer's questions.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.
About usLife sciences fundraising advisory FAQ
What does a life sciences fundraising advisor do?
How do life sciences startups get funding?
Is life sciences funding coming back in 2026?
Should you hire an investment bank or a fundraising advisor?
How are life sciences startups valued?
How much does life sciences fundraising advisory cost?
Industries we work with
Pharmaceuticals
- Pharmaceuticals
- Life Sciences
- PharmaTech
Related industries
Raising for a life sciences company?
Send us your stage and your next milestone. We'll tell you which questions investors will ask first.



